Medigene AG: Medigene AG Exercises First Tranche of the Standby Equity Purchase Agreement

Planegg/Martinsried (pta025/24.01.2025/18:10 UTC+1)

Medigene AG (Medigene or the "Company", FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, announces that it has today notified Yorkville of the exercise of the first tranche under the Standby Equity Purchase Agreement ("SEPA") entered into with a fund managed by Yorkville Advisors Global, LP ("Yorkville").

The Company's Management Board has therefore resolved to increase the Company's share capital by EUR 150,000.00 from EUR 14,737,594.00 to EUR 14,887,594.00 by issuing 150,000 new no-par value registered shares with a pro rata amount of the share capital of EUR 1.00 and with full dividend entitlement from January 1, 2024. Shareholders' subscription rights were excluded. Only Yorkville is authorized to subscribe to the new shares.

The subscription price is equal to 95% of the average of the volume-weighted average price of the Medigene share on each of the five trading days following the publication of this ad hoc announcement and will be determined after the end of these five trading days.

Immediately after the determination of the subscription price, the capital increase will be implemented and the implementation of the capital increase will be registered for entry in the commercial register.

(end)

Emitter:	Medigene AG Lochhamer Straße 11 82152 Planegg/Martinsried Germany
Contact Person:	Medigene PR/IR
Phone:	+49 89 2000 3333 01
E-Mail:	investor@medigene.com
Website:	www.medigene.de
ISIN(s):	DE000A40ESG2 (Share)
Stock Exchange(s):	Regulated Market in Frankfurt; Free Market in Berlin, Dusseldorf, Hamburg, Hannover, Munich, Stuttgart, Tradegate